{"filing":{"accession_number":"0001651625-26-000018","cik":"0001651625","ticker":"ACIU","company_name":"AC Immune SA","form":"6-K","filing_date":"2026-08-20","report_date":"2026-08-20","primary_document":"aciu-20260820x6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1651625/000165162526000018/aciu-20260820x6k.htm"},"events":[{"id":28681,"run_id":26244,"accession_number":"0001651625-26-000018","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces positive preliminary Phase 1 clinical trial data for ACI-19764, an NLRP3 inhibitor. The disclosure reports safety, tolerability, pharmacokinetics, and pharmacodynamic results from a first-in-human study, including confirmed brain penetration and dose-dependent IL-1beta inhibition. While this is a clinical development milestone rather than a discrete event like M\u0026A or executive change, it represents material operational progress for a clinical-stage biopharmaceutical company that would affect a reasonable investor's assessment of the company's pipeline and therapeutic potential.","company_name":"AC Immune SA","ticker":"ACIU","filing_date":"2026-08-20","form":"6-K","submitted_at":null,"items":[{"id":30706,"accession_number":"0001651625-26-000018","item_number":"EX-99.1","item_title":"aciu-20260820xex99d1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces positive preliminary Phase 1 clinical trial data for ACI-19764, an NLRP3 inhibitor. The disclosure reports safety, tolerability, pharmacokinetics, and pharmacodynamic results from a first-in-human study, including confirmed brain penetration and dose-dependent IL-1beta inhibition. While this is a clinical development milestone rather than a discrete event like M\u0026A or executive change, it represents material operational progress for a clinical-stage biopharmaceutical company that would affect a reasonable investor's assessment of the company's pipeline and therapeutic potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-20T11:02:37.640819+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30706,"accession_number":"0001651625-26-000018","item_number":"EX-99.1","item_title":"aciu-20260820xex99d1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces positive preliminary Phase 1 clinical trial data for ACI-19764, an NLRP3 inhibitor. The disclosure reports safety, tolerability, pharmacokinetics, and pharmacodynamic results from a first-in-human study, including confirmed brain penetration and dose-dependent IL-1beta inhibition. While this is a clinical development milestone rather than a discrete event like M\u0026A or executive change, it represents material operational progress for a clinical-stage biopharmaceutical company that would affect a reasonable investor's assessment of the company's pipeline and therapeutic potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-20T11:02:37.640819+00:00","company_name":"AC Immune SA","ticker":"ACIU","filing_date":"2026-08-20"}]}